# Giovanni Cammarota

List of Publications by Year
in descending order



| 362 | 14,725 | 20817 60 | 25787 108 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 366 | 366 | 366 | 14736 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Role of gut microbiome on immunotherapy efficacy in melanoma. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6. | 3.3 | 12 |
| 2 | Evaluating Donor Microbiome Before Fecal Microbiota Transplantation. Gastroenterology, 2022, 162, 993-994. | 1.3 | 3 |
| 3 | Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile Infection: Systematic Review and Meta-analysis. Journal of the Canadian Association of Gastroenterology, 2022, 5, e1-e11. | 0.3 | 14 |
| 4 | Fecal Microbiota Transplantation in Children. , 2022, , 709-712. | | 0 |
| 5 | How the gut parasitome affects human health. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210915. | 3.2 | 19 |
| 6 | Rummeliibacillus suwonensis: First Time Isolation from Human Feces by Culturomics. Current Microbiology, 2022, 79, . | 2.2 | 0 |
| 7 | Risk Factors, Diagnosis, and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. Microorganisms, 2022, 10, 1315. | 3.6 | 7 |
| 8 | Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 1627-1634. | 4.4 | 24 |
| 9 | A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterology Journal, 2021, 9, 229-247. | 3.8 | 66 |
| 10 | Autologous faecal microbiota transplantation for type 1 diabetes: a potential mindshift in therapeutic microbiome manipulation?. Gut, 2021, 70, 2-3. | 12.1 | 45 |
| 11 | Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. Expert Review of Gastroenterology and Hepatology, 2021, 15, 599-622. | 3.0 | 41 |
| 12 | Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?. American Journal of Gastroenterology, 2021, 116, 1360-1361. | 0.4 | 2 |
| 13 | <i>Clostridioides difficile</i> infection during the COVID-19 pandemic: a gut microbiotaâ€“based relationship. Polish Archives of Internal Medicine, 2021, 131, 116-117. | 0.4 | 2 |
| 14 | Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nature Communications, 2021, 12, 1926. | 12.8 | 22 |
| 15 | SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266. | 8.1 | 5 |
| 16 | Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. Digestive and Liver Disease, 2021, 53, 1428-1432. | 0.9 | 10 |
| 17 | Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 2605. | 2.4 | 12 |
| 18 | Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. Digestive and Liver Disease, 2021, 53, 1527-1528. | 0.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110258. | 4.8 | 52 |
| 20 | The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181. | 5.6 | 43 |
| 21 | Residual Gastrointestinal Symptoms after Fecal Microbiota Transplantation for Clostridioides difficile Infection: A Matter of Efficacy Rather Than Safety?. Gastroenterology, 2021, 161, 1344. | 1.3 | 0 |
| 22 | Systematic review: the global incidence of faecal microbiota transplantationâ€related adverse events from 2000 to 2020. Alimentary Pharmacology and Therapeutics, 2021, 53, 33-42. | 3.7 | 115 |
| 23 | Improved gut microbiota features after the resolution of SARSâ€'CoVâ€'2 infection. Gut Pathogens, 2021, 13, 62. | 3.4 | 10 |
| 24 | Fecal Microbiome Transplantation for Recurrent Clostridioides difficile Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 470-476. | 0.9 | 3 |
| 25 | COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World Journal of Gastroenterology, 2021, 27, 7433-7445. | 3.3 | 37 |
| 26 | Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes, 2021, 13, 1994834. | 9.8 | 21 |
| 27 | COVID-19 in celiac disease: a multicentric retrospective cohort study. European Review for Medical and Pharmacological Sciences, 2021, 25, 4400-4404. | 0.7 | 5 |
| 28 | How to define a quadruple aim framework to assess value in critical pathway of the patients with Clostridioides difficile infection. European Review for Medical and Pharmacological Sciences, 2021, 25, 4597-4610. | 0.7 | 2 |
| 29 | Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period. European Review for Medical and Pharmacological Sciences, 2021, 25, 5826-5835. | 0.7 | 1 |
| 30 | The Italian National Faecal Microbiota Transplantation Program: a coordinated effort against Clostridioides difficile infection. Annali Dell'Istituto Superiore Di Sanita, 2021, 57, 239-243. | 0.4 | 1 |
| 31 | Laboratory handling practice for faecal microbiota transplantation. Journal of Applied Microbiology, 2020, 128, 893-898. | 3.1 | 7 |
| 32 | <p>Treatment of Recurrent <em>Clostridioides difficile</em> Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease</p>. Journal of Inflammation Research, 2020, Volume 13, 563-570. | 3.5 | 9 |
| 33 | Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. Alimentary Pharmacology and Therapeutics, 2020, 52, 902-903. | 3.7 | 9 |
| 34 | Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study. Digestive and Liver Disease, 2020, 52, 1390-1395. | 0.9 | 16 |
| 35 | Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. Beneficial Microbes, 2020, 11, 519-525. | 2.4 | 13 |
| 36 | The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflammatory Bowel Diseases, 2020, 26, 1306-1314. | 1.9 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Letter: faecal microbiota transplantation for irritable bowel syndromeâ€"room for improvement. Alimentary Pharmacology and Therapeutics, 2020, 52, 923-924. | 3.7 | 7 |
| 38 | Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. Future Microbiology, 2020, 15, 1173-1183. | 2.0 | 18 |
| 39 | Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nature Communications, 2020, 11, 4333. | 12.8 | 82 |
| 40 | Esophageal microbiome signature in patients with Barrettâ€™s esophagus and esophageal adenocarcinoma. PLoS ONE, 2020, 15, e0231789. | 2.5 | 58 |
| 41 | Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila. Digestive and Liver Disease, 2020, 52, 1002-1010. | 0.9 | 23 |
| 42 | Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. Journal of Clinical Medicine, 2020, 9, 1757. | 2.4 | 65 |
| 43 | Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. The Lancet Gastroenterology and Hepatology, 2020, 5, 430-432. | 8.1 | 108 |
| 44 | Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 635-648. | 17.8 | 172 |
| 45 | Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563. | 12.1 | 110 |
| 46 | Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opinion on Biological Therapy, 2020, 20, 343-351. | 3.1 | 29 |
| 47 | Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1909-1915. | 2.8 | 5 |
| 48 | Microbiome: what intensivists should know. Minerva Anestesiologica, 2020, 86, 777-785. | 1.0 | 11 |
| 49 | Oral supplementation with lactobacilli to prevent colorectal cancer in preclinical models. Minerva Gastroenterologica E Dietologica, 2020, 66, 48-69. | 2.2 | 3 |
| 50 | OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE. Digestive and Liver Disease, 2019, 51, e90. | 0.9 | 0 |
| 51 | Letter: improvement of clinical outcomes by metformin in metabolic liver diseaseâ€"a microbiotaâ€dependent mechanism?. Alimentary Pharmacology and Therapeutics, 2019, 50, 474-474. | 3.7 | 0 |
| 52 | Fecal microbiota transplant for C.Âdifficile infection: Just say yes. Anaerobe, 2019, 60, 102109. | 2.1 | 8 |
| 53 | OC.11.4 CHARACTERIZATION OF ESOPHAGEAL MICROBIOTA IN PATIENTS WITH BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA. Digestive and Liver Disease, 2019, 51, e107. | 0.9 | 0 |
| 54 | FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 1021. | 2.4 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Gut microbiome beats two to zero host genome. Hepatobiliary Surgery and Nutrition, 2019, 8, 378-380. | 1.5 | 1 |
| 56 | OC.03.4 DECREASE OF BLOODSTREAM INFECTION RATES IN PATIENTS WITH CLOSTRIDIUM DIFFICILE INFECTION TREATED WITH FAECAL MICROBIOTA TRANSPLANTATION: A PROSPECTIVE OBSERVATIONAL COHORT STUDY. Digestive and Liver Disease, 2019, 51, e84-e85. | 0.9 | 0 |
| 57 | The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. International Journal of Molecular Sciences, 2019, 20, 501. | 4.1 | 39 |
| 58 | Systematic review with metaâ€analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2019, 50, 240-248. | 3.7 | 144 |
| 59 | Emerging drugs for the treatment of clostridium difficile. Expert Opinion on Emerging Drugs, 2019, 24, 17-28. | 2.4 | 11 |
| 60 | P128 Histological activity predicts clinical relapse in patients with ulcerative colitis in endoscopic remission. Journal of Crohn's and Colitis, 2019, 13, S152-S152. | 1.3 | 2 |
| 61 | FMT for ulcerative colitis: closer to the turning point. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 266-268. | 17.8 | 18 |
| 62 | A Durum Wheat Variety-Based Product Is Effective in Reducing Symptoms in Patients with Non-Celiac Gluten Sensitivity: A Double-Blind Randomized Cross-Over Trial. Nutrients, 2019, 11, 712. | 4.1 | 13 |
| 63 | Impact evaluation of a Critical Pathway for patients with Clostridium difficile infection: A pre-post analysis in a Third Level Referral Center. International Journal of Infectious Diseases, 2019, 80, 105-110. | 3.3 | 3 |
| 64 | Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With RecurrentClostridioides difficileInfection Treated With Fecal Microbiota Transplantation or Antibiotics. Annals of Internal Medicine, 2019, 171, 695. | 3.9 | 81 |
| 65 | Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation, 2019, 2019, 1-10. | 3.0 | 39 |
| 66 | International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 2019, 68, 2111-2121. | 12.1 | 290 |
| 67 | Reflux symptoms in professional opera soloists. Digestive and Liver Disease, 2019, 51, 798-803. | 0.9 | 5 |
| 68 | Bacteriocins and Bacteriophages: Therapeutic Weapons for Gastrointestinal Diseases?. International Journal of Molecular Sciences, 2019, 20, 183. | 4.1 | 70 |
| 69 | Coeliac disease under a microscope: Histological diagnostic features and confounding factors. Computers in Biology and Medicine, 2019, 104, 335-338. | 7.0 | 3 |
| 70 | Current and future targets for faecal microbiota transplantation. Human Microbiome Journal, 2019, 11, 100045. | 3.8 | 7 |
| 71 | Fecal microbiota transplantation for TKI-induced diarrhea in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 615-615. | 1.6 | 4 |
| 72 | Clostridium difficile: trend in an Italian Tertiary Care Hospital during fifteen years, 2002-2016. Minerva Medica, 2019, 110, 168-171. | 0.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohnâ€™s Disease. Digestive Diseases, 2018, 36, 184-193. | 1.9 | 27 |
| 74 | Faecal Microbiota Transplantation as Emerging Treatment in European Countries. Advances in Experimental Medicine and Biology, 2018, 1050, 177-195. | 1.6 | 7 |
| 75 | Letter by Ianiro et al Regarding Article, â€œEffect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calciumâ€. Circulation, 2018, 137, 213-214. | 1.6 | 1 |
| 76 | Faecal microbiota transplantation in clinical practice. Gut, 2018, 67, 196.2-197. | 12.1 | 18 |
| 77 | Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. Digestive Diseases, 2018, 36, 56-65. | 1.9 | 146 |
| 78 | Fecal calprotectin in management of Clostridium difficile infection: a longitudinal study. Scandinavian Journal of Gastroenterology, 2018, 53, 567-572. | 1.5 | 8 |
| 79 | Response to: Comment on â€œGut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Diseaseâ€. Mediators of Inflammation, 2018, 2018, 1-2. | 3.0 | 5 |
| 80 | Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infectionâ€”single versus multiple infusions. Alimentary Pharmacology and Therapeutics, 2018, 48, 152-159. | 3.7 | 117 |
| 81 | Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators of Inflammation, 2018, 2018, 1-7. | 3.0 | 62 |
| 82 | Wheat desensitization treatment in patients with gluten sensitivity. Postepy Dermatologii I Alergologii, 2018, 35, 320-322. | 0.9 | 2 |
| 83 | Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 1232-1244. | 3.8 | 137 |
| 84 | PC.01.7 RANDOMIZED CLINICAL TRIAL: SINGLE-INFUSION FMT VERSUS MULTIPLE-INFUSION FMT FOR THE TREATMENT OF SEVERE C. DIFFICILE INFECTION. Digestive and Liver Disease, 2018, 50, e66-e67. | 0.9 | 4 |
| 85 | Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 2018, 10, 1074. | 4.1 | 62 |
| 86 | Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: an update. Drugs of Today, 2018, 54, 123. | 1.1 | 17 |
| 87 | Helicobacter pylori in metabolic related diseases. Minerva Gastroenterologica E Dietologica, 2018, 64, 297-309. | 2.2 | 11 |
| 88 | Ipilimumab Adjuvant Therapy in Melanoma. New England Journal of Medicine, 2017, 376, 398-399. | 27.0 | 7 |
| 89 | European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580. | 12.1 | 793 |
| 90 | Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year cohort study: authors' reply. Clinical Microbiology and Infection, 2017, 23, 891. | 6.0 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clinical Microbiology and Infection, 2017, 23, 337.e1-337.e3. | 6.0 | 60 |
| 92 | Screening of colorectal cancer: present and future. Expert Review of Anticancer Therapy, 2017, 17, 1131-1146. | 2.4 | 123 |
| 93 | P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?. Digestive and Liver Disease, 2017, 49, e159. | 0.9 | 0 |
| 94 | P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis. Digestive and Liver Disease, 2017, 49, e158-e159. | 0.9 | 0 |
| 95 | Gut Microbiota and Cancer Patients: A Broad-Ranging Relationship. Mayo Clinic Proceedings, 2017, 92, 1605-1607. | 3.0 | 7 |
| 96 | Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. British Journal of Pharmacology, 2017, 174, 1426-1449. | 5.4 | 126 |
| 97 | Prevention and treatment of Clostridium difficile infection. Geriatric Care, 2017, 3, . | 0.2 | 0 |
| 98 | Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide. Gastroenterology Research and Practice, 2017, 2017, 1-11. | 1.5 | 119 |
| 99 | Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS ONE, 2017, 12, e0186575. | 2.5 | 23 |
| 100 | Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterology, 2017, 63, 420-430. | 0.5 | 22 |
| 101 | The gut microbiota: its anatomy and physiology over a lifetime. Minerva Gastroenterology, 2017, 63, 329-336. | 0.5 | 16 |
| 102 | Digestive Enzyme Supplementation in Gastrointestinal Diseases. Current Drug Metabolism, 2016, 17, 187-193. | 1.2 | 87 |
| 103 | Role and mechanisms of action ofEscherichia coliNissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World Journal of Gastroenterology, 2016, 22, 5505. | 3.3 | 141 |
| 104 | The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Digestive Diseases, 2016, 34, 269-278. | 1.9 | 105 |
| 105 | Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Digestive Diseases, 2016, 34, 279-285. | 1.9 | 22 |
| 106 | P.12.2 DIAGNOSIS OF CELIAC DISEASE IN ADULTS WITHOUT DUODENAL BIOPSY IN THE PRESENCE OF POSITIVE ANTI-ENDOMYSIUM ANTIBODIES AND ANTI-TRANSGLUTAMINASE ANTIBODIES. Digestive and Liver Disease, 2016, 48, e185. | 0.9 | 0 |
| 107 | Gut Virome and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1708-1712. | 1.9 | 39 |
| 108 | Rifaximin for the treatment of irritable bowel syndrome â€“ a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 983-991. | 2.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis. Transplantation Proceedings, 2016, 48, 402-407. | 0.6 | 26 |
| 110 | Endoscopic evaluation of celiac disease. Endoscopy International Open, 2016, 04, E547-E548. | 1.8 | 0 |
| 111 | Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Applied and Environmental Microbiology, 2016, 82, 6633-6644. | 3.1 | 85 |
| 112 | Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Digestive and Liver Disease, 2016, 48, 1043-1047. | 0.9 | 6 |
| 113 | The Role of Biomarkers in Diverticular Disease. Journal of Clinical Gastroenterology, 2016, 50, S26-S28. | 2.2 | 19 |
| 114 | P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?. Digestive and Liver Disease, 2016, 48, e157. | 0.9 | 0 |
| 115 | P.08.11 THE POSITION WITHIN THE OESOPHAGEAL CIRCUMFERENCE PREDICTS DYSPLASIA IN SHORT SEGMENT BARRETT'S ESOPHAGUS: A 7-YEAR RETROSPECTIVE SERIES OF 341 LESIONS. Digestive and Liver Disease, 2016, 48, e168-e169. | 0.9 | 0 |
| 116 | OC.12.9 FECAL MICROBIOTA TRANSPLANTATION FOR RECURRENT C. DIFFICILE INFECTION: A 2-YEAR EXPERIENCE FROM A EUROPEAN REFERRAL CENTRE. Digestive and Liver Disease, 2016, 48, e118. | 0.9 | 0 |
| 117 | Real-time diagnosis of H. pylori infection during endoscopy: Accuracy of an innovative tool (EndoFaster). United European Gastroenterology Journal, 2016, 4, 339-342. | 3.8 | 16 |
| 118 | Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2016, 7, e139. | 2.5 | 19 |
| 119 | Circulating endothelial-derived apoptotic microparticles and insulin resistance in non-diabetic patients with chronic heart failure. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1259-1267. | 2.3 | 20 |
| 120 | Olmesartan-associated sprue-like enteropathy: know your enemy. Scandinavian Journal of Gastroenterology, 2016, 51, 891-891. | 1.5 | 1 |
| 121 | Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. Digestive and Liver Disease, 2016, 48, 391-398. | 0.9 | 17 |
| 122 | Probiotics in prevention and treatment of obesity: a critical view. Nutrition and Metabolism, 2016, 13, 14. | 3.0 | 235 |
| 123 | Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World Journal of Gastroenterology, 2016, 22, 9727. | 3.3 | 5 |
| 124 | The role of diet on gut microbiota composition. European Review for Medical and Pharmacological Sciences, 2016, 20, 4742-4749. | 0.7 | 149 |
| 125 | Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Alimentary Pharmacology and Therapeutics, 2015, 41, 835-843. | 3.7 | 467 |
| 126 | Decrease in Surgery for Clostridium difficile Infection After Starting a Program to Transplant Fecal Microbiota. Annals of Internal Medicine, 2015, 163, 487-488. | 3.9 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. Journal of Translational Medicine, 2015, 13, 220. | 4.4 | 10 |
| 128 | Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrentClostridium difficileinfection. Alimentary Pharmacology and Therapeutics, 2015, 42, 1030-1030. | 3.7 | 11 |
| 129 | Effect of short term aerobic exercise on fasting and postprandial lipoprotein subfractions in healthy sedentary men. Lipids in Health and Disease, 2015, 14, 151. | 3.0 | 10 |
| 130 | The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. , 2015, 149, 191-212. | | 139 |
| 131 | Current technologies for the endoscopic assessment of duodenal villous pattern in celiac disease. Computers in Biology and Medicine, 2015, 65, 308-314. | 7.0 | 11 |
| 132 | Tu1533 Esophageal Posterior and Right Wall Are the Most Common Localizations of Barrett's Esophagus. Gastrointestinal Endoscopy, 2015, 81, AB499. | 1.0 | 0 |
| 133 | Development and Validation of an Endoscopic Classification of Diverticular Disease of the Colon: The DICA Classification. Digestive Diseases, 2015, 33, 68-76. | 1.9 | 62 |
| 134 | Fecal Microbiota Transplantation for Recurrent C. difficile Infection in a Patient with Chronic Refractory Ulcerative Colitis. Journal of Crohn's and Colitis, 2015, 9, 367-367. | 1.3 | 5 |
| 135 | Fecal Microbiota Transplantation in Inflammatory Bowel Disease. Medicine (United States), 2014, 93, e97. | 1.0 | 77 |
| 136 | Systematic review: sprue-like enteropathy associated with olmesartan. Alimentary Pharmacology and Therapeutics, 2014, 40, 16-23. | 3.7 | 117 |
| 137 | Letter: telmisartan associated enteropathy â€“ is there any class effect? Authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 570-570. | 3.7 | 15 |
| 138 | Letter: faecal microbiota transplantation - not a one-size-fits-all approach. Alimentary Pharmacology and Therapeutics, 2014, 40, 119-119. | 3.7 | 4 |
| 139 | Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2014, 48, 693-702. | 2.2 | 375 |
| 140 | Role of Microbiota and Innate Immunity in RecurrentClostridium difficileInfection. Journal of Immunology Research, 2014, 2014, 1-8. | 2.2 | 43 |
| 141 | Moderately Severe Acute Pancreatitis Associated With Riluzole. Journal of Clinical Gastroenterology, 2014, 48, 563. | 2.2 | 12 |
| 142 | OC.05.5 DEVELOPMENT AND VALIDATION OF AN ENDOSCOPIC CLASSIFICATION OF DIVERTICULAR DISEASE OF THE COLON: THE DICA CLASSIFICATION. Digestive and Liver Disease, 2014, 46, S14-S15. | 0.9 | 1 |
| 143 | OC.11.3 MUCOSAL HEALING DOES NOT CORRESPOND TO HISTOLOGICAL HEALING IN ULCERATIVE COLITIS. Digestive and Liver Disease, 2014, 46, S26-S27. | 0.9 | 0 |
| 144 | P090 Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action. Journal of Crohn's and Colitis, 2014, 8, S99-S100. | 1.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | OC.13.4 MULTIPARAMETRIC EVALUATION OF CROHN'S DISEASE: INTESTINAL HEALING BEYOND MUCOSAL HEALING. Digestive and Liver Disease, 2014, 46, S31. | 0.9 | 0 |
| 146 | P182 Multiparametric evaluation of Crohn's disease: possible role of intestinal healing beyond mucosal healing. Journal of Crohn's and Colitis, 2014, 8, S138. | 1.3 | 0 |
| 147 | OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION. Digestive and Liver Disease, 2014, 46, S35. | 0.9 | 0 |
| 148 | P184 Mucosal healing does not correspond to histological healing in ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, S139. | 1.3 | 0 |
| 149 | Dramatic improvement of parkinsonian symptoms after gluten-free diet introduction in a patient with silent celiac disease. Journal of Neurology, 2014, 261, 443-445. | 3.6 | 11 |
| 150 | Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation?. Internal and Emergency Medicine, 2014, 9, 365-373. | 2.0 | 98 |
| 151 | Nickel Free-Diet Enhances the Helicobacter pylori Eradication Rate: A Pilot Study. Digestive Diseases and Sciences, 2014, 59, 1851-1855. | 2.3 | 30 |
| 152 | P.18.4 EFFICACY OF ANTIOXIDANT THERAPY IN IMPROVING PAINFUL CHRONIC PANCREATITIS: A SYSTEMATIC REVIEW. Digestive and Liver Disease, 2014, 46, S128. | 0.9 | 0 |
| 153 | P.15.1 PROSPECTIVE VALIDATION OF ENDOFASTER FOR A REALTIME DIAGNOSIS OF H. PYLORI INFECTION DURING UPPER ENDOSCOPY. Digestive and Liver Disease, 2014, 46, S111. | 0.9 | 0 |
| 154 | P.06.9 INFLIXIMAB IS NOT INCREASING COLONIC CANCER RISK ASSOCIATED TO CHRONIC COLITIS IN MICE. Digestive and Liver Disease, 2014, 46, S73. | 0.9 | 0 |
| 155 | P.17.13 WHITE MULBERRY SUPPLEMENTATION AS ADJUVANT TREATMENT OF OBESITY. Digestive and Liver Disease, 2014, 46, S124. | 0.9 | 1 |
| 156 | Faecal transplantation for Clostridium difficile infection. Three cases treated in Italy. Digestive and Liver Disease, 2014, 46, 475. | 0.9 | 6 |
| 157 | Fecal Microbiota Transplantation. Journal of Clinical Gastroenterology, 2014, 48, S80-S84. | 2.2 | 33 |
| 158 | Role of Yeasts in Healthy and Impaired Gut Microbiota: The Gut Mycome. Current Pharmaceutical Design, 2014, 20, 4565-4569. | 1.9 | 51 |
| 159 | Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives. Current Drug Targets, 2014, 15, 762-770. | 2.1 | 74 |
| 160 | Culture-guided treatment approach forHelicobacter pyloriinfection: Review of the literature. World Journal of Gastroenterology, 2014, 20, 5205. | 3.3 | 38 |
| 161 | Image-Enhanced Endoscopy with I-scan Technology for the Evaluation of Duodenal Villous Patterns. Digestive Diseases and Sciences, 2013, 58, 1287-1292. | 2.3 | 26 |
| 162 | Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice. Digestive and Liver Disease, 2013, 45, 1017-1021. | 0.9 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response. Cytokine and Growth Factor Reviews, 2013, 24, 455-466. | 7.2 | 50 |
| 164 | Pre- and Posttherapy Assessment of Intestinal Soluble Mediators in IBD: Where We Stand and Future Perspectives. Mediators of Inflammation, 2013, 2013, 1-9. | 3.0 | 5 |
| 165 | Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. BioMed Research International, 2013, 2013, 1-9. | 1.9 | 156 |
| 166 | Endoscopic tools for the diagnosis and evaluation of celiac disease. World Journal of Gastroenterology, 2013, 19, 8562. | 3.3 | 32 |
| 167 | Gluten-related recurrent peripheral facial palsy: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 667-668. | 1.9 | 6 |
| 168 | Tissue-Infiltrating Lymphocytes Analysis Reveals Large Modifications of the Duodenal â€œImmunological Nicheâ€•in Coeliac Disease After Gluten-Free Diet. Clinical and Translational Gastroenterology, 2012, 3, e28. | 2.5 | 25 |
| 169 | Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Digestive and Liver Disease, 2012, 44, 1032-1036. | 0.9 | 16 |
| 170 | Review article: biofilm formation by <scp>H</scp>elicobacter pylori as a target for eradication of resistant infection. Alimentary Pharmacology and Therapeutics, 2012, 36, 222-230. | 3.7 | 84 |
| 171 | Microscopic colitis. World Journal of Gastroenterology, 2012, 18, 6206. | 3.3 | 40 |
| 172 | New insights on the role of T cells in the pathogenesis of celiac disease. Journal of Biological Regulators and Homeostatic Agents, 2012, 26, 171-9. | 0.7 | 14 |
| 173 | I-Scan Technology is Useful to Improve the Rate of Gastric Varices Diagnosis in Patients With Portal Hypertension. Gastroenterology, 2011, 140, S-753. | 1.3 | 0 |
| 174 | P.1.38: SEQUENTIAL AND STANDARD LEVOFLOXACIN-BASED H. PYLORI ERADICATING REGIMENS COMPARED TO QUADRUPLE THERAPY: EFFECT OF LEVOFLOXACIN DOSAGE AND WAY OF ADMINISTRATION. Digestive and Liver Disease, 2011, 43, S160-S161. | 0.9 | 0 |
| 175 | P.1.57: LGR5+ INTESTINAL STEM CELLS INVOLVEMENT IN EPITHELIAL REGENERATION FOLLOWING GLUTEN FREE DIET IN CELIAC PATIENTS. Digestive and Liver Disease, 2011, 43, S167. | 0.9 | 0 |
| 176 | P.1.303: HIGH DOSE AMOXICILLIN-BASED FIRST LINE REGIMEN IS EQUIVALENT TO SEQUENTIAL THERAPY IN THE ERADICATION OF H. PYLORI INFECTION. Digestive and Liver Disease, 2011, 43, S248-S249. | 0.9 | 0 |
| 177 | Combined atherogenic effects of celiac disease and type 1 diabetes mellitus. Atherosclerosis, 2011, 217, 531-535. | 0.8 | 48 |
| 178 | Spectral Endoscopic Imaging. Journal of Clinical Gastroenterology, 2011, 45, 6-15. | 2.2 | 18 |
| 179 | Lactose Intolerance in Systemic Nickel Allergy Syndrome. International Journal of Immunopathology and Pharmacology, 2011, 24, 535-537. | 2.1 | 10 |
| 180 | Gastrointestinal: An unusual gastric flat lesion: amyloidosis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 784-784. | 2.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Alcohol and Alcoholism, 2011, 46, 312-317. | 1.6 | 173 |
| 182 | Reflux symptoms in wind instrument players. Alimentary Pharmacology and Therapeutics, 2010, 31, 593-600. | 3.7 | 11 |
| 183 | The combined application of advanced endoscopic imaging techniques may increase the duodenal villous morphology definition in suspected celiac disease. Digestive and Liver Disease, 2010, 42, 595-596. | 0.9 | 2 |
| 184 | OC.06.3 METABOLIC SYNDROME PROMOTES THE OCCURRENCE OF PRE-NEOPASTIC LESIONS OF THE COLONIC MUCOSA. Digestive and Liver Disease, 2010, 42, S84. | 0.9 | 0 |
| 185 | OC.09.1 DYNAMICS OF INTESTINAL REGENERATION FOLLOWING GLUTEN-FREE DIET IN CELIAC PATIENTS AND ROLE OF CIRCULATING HEMATOPOIETIC STEM CELLS. Digestive and Liver Disease, 2010, 42, S91. | 0.9 | 0 |
| 186 | Tired legsâ€”a gut diagnosis. Lancet, The, 2010, 376, 1798. | 13.7 | 7 |
| 187 | Biofilm Demolition and Antibiotic Treatment to Eradicate Resistant Helicobacter pylori: A Clinical Trial. Clinical Gastroenterology and Hepatology, 2010, 8, 817-820.e3. | 4.4 | 79 |
| 188 | Can chronic gastritis cause an increase in fecal calprotectin concentrations?. World Journal of Gastroenterology, 2010, 16, 3406. | 3.3 | 19 |
| 189 | Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity. Annals of Clinical and Laboratory Science, 2010, 40, 3-9. | 0.2 | 21 |
| 190 | Celiac Disease in the 21st Century: Issues of Under-and Over-Diagnosis. International Journal of Immunopathology and Pharmacology, 2009, 22, 1-7. | 2.1 | 21 |
| 191 | Emerging technologies in upper gastrointestinal endoscopy and celiac disease. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 47-56. | 1.7 | 41 |
| 192 | The Interaction Between Small Intestinal Bacterial Overgrowth and Warfarin Treatment. American Journal of Gastroenterology, 2009, 104, 2364-2365. | 0.4 | 7 |
| 193 | Involvement of central immunity in uncomplicated diverticular disease. Scandinavian Journal of Gastroenterology, 2009, 44, 108-115. | 1.5 | 32 |
| 194 | Cellular Mediators of Inflammation: Tregs and<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msub><mml:mtext>T</mml:mtext><mml:mtext>H</mml:mtext></mml:ms mathvariant="bold">17</mml:mn></mml:math>Cells in Gastrointestinal Diseases. Mediators of Inflammation, 2009, 2009, 1-11. | 3.0 | 28 |
| 195 | Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009, 49, 1877-1887. | 7.3 | 1,138 |
| 196 | T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. Clinical and Experimental Immunology, 2009, 158, 106-114. | 2.6 | 22 |
| 197 | Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: Correlation with dietary treatment. Human Immunology, 2009, 70, 430-435. | 2.4 | 35 |
| 198 | CYCLIC TREATMENT WITH MESALAZINE IN PREVENTING RECURRENCE OF SMALL INTESTINAL BACTERIAL OVERGROWTH AFTER ANTIBIOTIC TREATMENT. Digestive and Liver Disease, 2009, 41, S67. | 0.9 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Free Peritoneal Gas Accumulation Caused by Pneumatosis Coli After Diagnostic Gastrointestinal Endoscopy. Clinical Gastroenterology and Hepatology, 2009, 7, A18. | 4.4 | 2 |
| 200 | Patchy Left-Sided Colitis: Primary Eosinophilic Colitis or Paraneoplastic Syndrome?. Clinical Gastroenterology and Hepatology, 2009, 7, e61. | 4.4 | 1 |
| 201 | Waterâ€immersion Technique During Standard Upper Endoscopy May Be Useful to Drive the Biopsy Sampling of Duodenal Mucosa in Children With Celiac Disease. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 411-416. | 1.8 | 26 |
| 202 | The Water Immersion Technique is Easy to Learn for Routine Use During EGD for Duodenal Villous Evaluation. Journal of Clinical Gastroenterology, 2009, 43, 244-248. | 2.2 | 33 |
| 203 | Quick Test: A New Test for the Diagnosis of Duodenal Hypolactasia. Digestive Diseases and Sciences, 2008, 53, 1589-1592. | 2.3 | 15 |
| 204 | Increased Frequency of Ig Heavy-Chain HS1,2-A Enhancer *2 Allele in Dermatitis Herpetiformis, Plaque Psoriasis, and Psoriatic Arthritis. Journal of Investigative Dermatology, 2008, 128, 1920-1924. | 0.7 | 34 |
| 205 | Lowâ€dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms. Alimentary Pharmacology and Therapeutics, 2008, 28, 1003-1012. | 3.7 | 54 |
| 206 | OC3.08.2 SMALL INTESTINAL BACTERIAL OVERGROWTH IN A CHILDREN POPULATION AFFECTED BY IRRITABLE BOWEL SYNDROME: A CASE-CONTROL STUDY. Digestive and Liver Disease, 2008, 40, S59. | 0.9 | 0 |
| 207 | OC3.09.2 EFFECT OF LACTOSE AMOUNT PRESENT IN DRUGS ON H2 EXCRETION AND GASTROINTESTINAL SYMPTOMS. Digestive and Liver Disease, 2008, 40, S62-S63. | 0.9 | 0 |
| 208 | PA.10 ROLE OF VIRTUAL CHROMO-ENDOSCOPY (CVC) FOR DETECTION OF PATIENTS WITH COMPLICATED GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD): APILOTSTUDY. Digestive and Liver Disease, 2008, 40, S79. | 0.9 | 0 |
| 209 | PA.29 IMPACT OF L. REUTERII SUPPLEMENTATION ON ANTI-H. PYLORI SECOND LINE THERAPY-RELATED. Digestive and Liver Disease, 2008, 40, S86. | 0.9 | 0 |
| 210 | PA.49 LACTOSE MALABSORPTION IN PATIENTS AFFECTED BY RECURRENT VAGINITIS. Digestive and Liver Disease, 2008, 40, S93. | 0.9 | 0 |
| 211 | PA.53 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) IN PATIENTS WITH DUODENOGASTRIC REFLUX (DGR) POST-CHOLECYSTECTOMY. Digestive and Liver Disease, 2008, 40, S94-S95. | 0.9 | 0 |
| 212 | PA.55 SMALL INTESTINAL BACTERIAL OVERGROWTH RECURRENCE AFTER ANTIBIOTIC THERAPY. Digestive and Liver Disease, 2008, 40, S95. | 0.9 | 0 |
| 213 | PA.58 SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) CAN AFFECT INTESTINAL PERMEABILITY. Digestive and Liver Disease, 2008, 40, S96. | 0.9 | 0 |
| 214 | PA.194 VALUE OF THE WATER-IMMERSION TECHNIQUE DURING UPPER ENDOSCOPY IN EVALUATING DUODENAL VILLOUS ATROPHY IN CELIAC CHILDREN. Digestive and Liver Disease, 2008, 40, S146-S147. | 0.9 | 0 |
| 215 | PA.248 MAGNIFICATION WITH VIRTUAL CHROMO-ENDOSCOPY (CVC) IN THE EVALUATION OF COLORECTAL MUCOSAL LESIONS: A PILOT STUDY. Digestive and Liver Disease, 2008, 40, S166. | 0.9 | 0 |
| 216 | PO.13 RIFAXIMIN VERSUS METRONIDAZOLE FOR THE TREATMENT OF SMALL BOWEL BACTERIAL OVERGROWTH. Digestive and Liver Disease, 2008, 40, S175. | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Optimal band imaging system: a new tool for enhancing the duodenal villous pattern in celiac disease. Gastrointestinal Endoscopy, 2008, 68, 352-357. | 1.0 | 30 |
| 218 | Skeletal muscle wastage in Crohn's disease: A pathway shared with heart failure?. International Journal of Cardiology, 2008, 127, 219-227. | 1.7 | 35 |
| 219 | Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. Human Immunology, 2008, 69, 837-839. | 2.4 | 27 |
| 220 | Fecal Calprotectin Concentrations in Patients with Small Intestinal Bacterial Overgrowth. Digestive Diseases, 2008, 26, 183-186. | 1.9 | 26 |
| 221 | Adverse Reactions to Food: Allergies and Intolerances. Digestive Diseases, 2008, 26, 96-103. | 1.9 | 24 |
| 222 | Classification of Malabsorption Syndromes. Digestive Diseases, 2008, 26, 104-111. | 1.9 | 13 |
| 223 | Celiac Disease: Whatâ€™s New about It?. Digestive Diseases, 2008, 26, 121-127. | 1.9 | 24 |
| 224 | Small Intestinal Bacterial Overgrowth Recurrence After Antibiotic Therapy. American Journal of Gastroenterology, 2008, 103, 2031-2035. | 0.4 | 112 |
| 225 | Reply to Souza et al.. Endoscopy, 2008, 40, 621-621. | 1.8 | 0 |
| 226 | Abnormal synthesis of IgA in coeliac disease and related disorders. Journal of Biological Regulators and Homeostatic Agents, 2008, 22, 99-104. | 0.7 | 5 |
| 227 | Faecal calprotectin concentrations in untreated coeliac patients. Scandinavian Journal of Gastroenterology, 2007, 42, 957-961. | 1.5 | 39 |
| 228 | Association between Hypothyroidism and Small Intestinal Bacterial Overgrowth. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4180-4184. | 3.6 | 108 |
| 229 | Fecal Calprotectin in First-Degree Relatives of Patients with Ulcerative Colitis. American Journal of Gastroenterology, 2007, 102, 132-136. | 0.4 | 29 |
| 230 | A highly accurate method for monitoring histological recovery in patients with celiac disease on a gluten-free diet using an endoscopic approach that avoids the need for biopsy: a double-center study. Endoscopy, 2007, 39, 46-51. | 1.8 | 41 |
| 231 | Reply to K. Rostami et al.. Endoscopy, 2007, 39, 574-574. | 1.8 | 1 |
| 232 | Hydrogen peroxide-related colitis (previously known as â€pseudolipomatosisâ€œ): a series of cases occurring in an epidemic pattern. Endoscopy, 2007, 39, 916-919. | 1.8 | 16 |
| 233 | Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 1026-1030. | 1.6 | 11 |
| 234 | Bile Acids and Total Bilirubin Detection in Saliva of Patients Submitted to Gastric Surgery and in Particular to Subtotal Billroth II Resection. Annals of Surgery, 2007, 245, 880-885. | 4.2 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Role of the â€œImmersion Techniqueâ€•in Diagnosing Celiac Disease With Villous Atrophy Limited to the Duodenal Bulb. Journal of Clinical Gastroenterology, 2007, 41, 571-575. | 2.2 | 27 |
| 236 | Fecal calprotectini in first degree relatives of patients with ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 669. | 1.9 | 0 |
| 237 | Reflux Symptoms in Professional Opera Choristers. Gastroenterology, 2007, 132, 890-898. | 1.3 | 60 |
| 238 | Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Digestive and Liver Disease, 2007, 39, 483-487. | 0.9 | 57 |
| 239 | Accuracy and Learning Curve and of the Water-Immersion Technique in Assessing Marked Villous Atrophy of the Duodenum: A Single Centre 4-Year Experience. Gastrointestinal Endoscopy, 2007, 65, AB339. | 1.0 | 1 |
| 240 | Role of the Fujinon Intelligent Chromo Endoscopy (FICE) forÂDetection of Patients with Suspected Celiac Disease (CD): A Pilot Study. Gastrointestinal Endoscopy, 2007, 65, AB356. | 1.0 | 0 |
| 241 | High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2007, 25, 781-786. | 3.7 | 94 |
| 242 | Increased prevalence of small intestinal bacterial overgrowth in patients with non-erosive reflux disease (NERD). Digestive and Liver Disease, 2006, 38, S81. | 0.9 | 0 |
| 243 | A case-control study comparing methylene blue directed biopsies and random biopsies for detecting pre-cancerous lesions in the follow-up of gastric cancer patients. Digestive and Liver Disease, 2006, 38, S149. | 0.9 | 1 |
| 244 | Duodenal metastasis from a primary angiosarcoma of the colon. Gastrointestinal Endoscopy, 2006, 63, 330. | 1.0 | 10 |
| 245 | Virulent strains of Helicobacter pylori and vascular diseases: A meta-analysis. American Heart Journal, 2006, 151, 1215-1222. | 2.7 | 60 |
| 246 | Management and treatment of lactose malabsorption. World Journal of Gastroenterology, 2006, 12, 187. | 3.3 | 159 |
| 247 | Prophylactic aspirin therapy does not increase faecal calprotectin concentrations. European Journal of Gastroenterology and Hepatology, 2006, 18, 965-967. | 1.6 | 21 |
| 248 | Biliary laryngopharyngeal reflux: a new pathological entity. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 128-132. | 1.8 | 34 |
| 249 | High accuracy and costâ€effectiveness of a biopsyâ€avoiding endoscopic approach in diagnosing coeliac disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 61-69. | 3.7 | 38 |
| 250 | A higher diagnostic profile is possible for microscopic colitis. Alimentary Pharmacology and Therapeutics, 2006, 24, 561-561. | 3.7 | 2 |
| 251 | Rifaximin-Based Regimens for Eradication of <i>Helicobacter pylori</i>: A Pilot Study. Digestive Diseases, 2006, 24, 195-200. | 1.9 | 25 |
| 252 | Accuracy of Laryngeal Examination during Upper Gastrointestinal Endoscopy for Premalignancy Screening: Prospective Study in Patients with and without Reflux Symptoms. Endoscopy, 2006, 38, 376-381. | 1.8 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Preliminary Laryngeal Examination During Magnifying Upper Gastrointestinal Video Endoscopy in Two Patients with Reflux Symptoms. Endoscopy, 2006, 38, 287-287. | 1.8 | 3 |
| 254 | Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay. Journal of Antimicrobial Chemotherapy, 2006, 57, 71-78. | 3.0 | 22 |
| 255 | Levofloxacin-Based Triple Therapy in First-Line Treatment for Helicobacter pylori Eradication. American Journal of Gastroenterology, 2006, 101, 1985-1990. | 0.4 | 67 |
| 256 | Third-line rescue therapy for Helicobacter pylori infection. World Journal of Gastroenterology, 2006, 12, 2313. | 3.3 | 39 |
| 257 | Laryngeal carcinoma and laryngo-pharyngeal reflux disease. Acta Otorhinolaryngologica Italica, 2006, 26, 260-3. | 1.5 | 24 |
| 258 | An Attempt of Specific Desensitising Treatment with Gliadin in Celiac Disease. International Journal of Immunopathology and Pharmacology, 2005, 18, 709-714. | 2.1 | 4 |
| 259 | Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2005, 21, 1241-1247. | 3.7 | 61 |
| 260 | Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2005, 21, 1391-1395. | 3.7 | 174 |
| 261 | Rifaximin doseâ€finding study for the treatment of small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2005, 22, 31-35. | 3.7 | 102 |
| 262 | Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence caseâ€“control study in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2005, 22, 1157-1160. | 3.7 | 161 |
| 263 | High-Resolution Magnifying Upper Endoscopy in a Patient with Patchy Celiac Disease. Digestive Diseases and Sciences, 2005, 50, 601-604. | 2.3 | 11 |
| 264 | Corkscrew Esophagus. New England Journal of Medicine, 2005, 352, 816-816. | 27.0 | 2 |
| 265 | High-Resolution Magnifying Video Endoscopy in Primary Intestinal Lymphangiectasia: a New Role for Endoscopy?. Endoscopy, 2005, 37, 607-607. | 1.8 | 15 |
| 266 | Double-balloon enteroscopy for diagnosis of a Meckel's diverticulum in a patient with GI bleeding of obscure origin. Gastrointestinal Endoscopy, 2005, 61, 779-781. | 1.0 | 29 |
| 267 | No more biopsy in the diagnostic work-up of celiac disease. Gastrointestinal Endoscopy, 2005, 62, 119-121. | 1.0 | 10 |
| 268 | High Prevalence of Celiac Disease in Patients with Lactose Intolerance. Digestion, 2005, 71, 106-110. | 2.3 | 77 |
| 269 | Regression of EI2-stage low-grade gastric MALT-lymphoma after H. pylori eradication. Hepato-Gastroenterology, 2005, 52, 975-7. | 0.5 | 1 |
| 270 | High efficacy of 1â€week doxycyclineâ€•and amoxicillinâ€based quadruple regimen in a cultureâ€guided, thirdâ€line treatment approach for <scp>Helicobacter pylori</scp> infection. Alimentary Pharmacology and Therapeutics, 2004, 19, 789-795. | 3.7 | 98 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Bacillus clausii therapy to reduce sideâ€effects of antiâ€Helicobacter pylori treatment: randomized, doubleâ€blind, placebo controlled trial. Alimentary Pharmacology and Therapeutics, 2004, 20, 1181-1188. | 3.7 | 156 |
| 272 | Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. American Journal of Cardiology, 2004, 94, 40-44. | 1.6 | 71 |
| 273 | High Prevalence of Hyperplastic Colonic Polyps in Acromegalic Subjects. Digestive Diseases and Sciences, 2004, 49, 662-666. | 2.3 | 13 |
| 274 | CASE REPORT: Celiac Disease and Chronic Urticaria Resolution: A Case Report. Digestive Diseases and Sciences, 2004, 49, 1489-1490. | 2.3 | 5 |
| 275 | Increased frequency of the immunoglobulin enhancer HS1,2 allele 2 in coeliac disease. Scandinavian Journal of Gastroenterology, 2004, 39, 1083-1087. | 1.5 | 38 |
| 276 | High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. International Journal of Antimicrobial Agents, 2004, 24, 433-438. | 2.5 | 38 |
| 277 | Reliability of the â€œimmersion techniqueâ€•during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. Gastrointestinal Endoscopy, 2004, 60, 223-228. | 1.0 | 46 |
| 278 | Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. Gastrointestinal Endoscopy, 2004, 60, 732-738. | 1.0 | 72 |
| 279 | Association of Laryngeal Cancer With Previous Gastric Resection. Annals of Surgery, 2004, 240, 817-824. | 4.2 | 25 |
| 280 | Helicobacter pylori Eradication Rate and Glycemic Control in Young Patients With Type 1 Diabetes. Journal of Pediatric Gastroenterology and Nutrition, 2004, 38, 422-425. | 1.8 | 23 |
| 281 | High-dose Versus Low-dose Clarithromycin in 1-week Triple Therapy, Including Rabeprazole and Levofloxacin, for Helicobacter pylori Eradication. Journal of Clinical Gastroenterology, 2004, 38, 110-114. | 2.2 | 18 |
| 282 | Helicobacter pylori and gastro-oesophageal reflux disease: Information on underlying pathology is not given. BMJ: British Medical Journal, 2004, 329, 402.1. | 2.3 | 1 |
| 283 | Levofloxacinâ€based triple therapy vs. quadruple therapy in secondâ€line Helicobacter pylori treatment: a randomized trial. Alimentary Pharmacology and Therapeutics, 2003, 18, 627-633. | 3.7 | 95 |
| 284 | 10 days levofloxacin-based triple therapy in second-line treatment for Helicobacter pylori eradication. Gastroenterology, 2003, 124, A359. | 1.3 | 3 |
| 285 | First-line treatment for Helicobacter pylori eradication: New moxifloxacin-based strategies. Gastroenterology, 2003, 124, A359. | 1.3 | 0 |
| 286 | Impact of bacillus clausii supplementation on anti Helicobacter pylori therapy related side effects: A randomized double blind placebo controlled study. Gastroenterology, 2003, 124, A361. | 1.3 | 0 |
| 287 | Post-cholecystectomy Alkaline Reactive Gatritis: A randomized trial comparing sucralfate versus rabeprazole or no treatment. Gastroenterology, 2003, 124, A456. | 1.3 | 1 |
| 288 | Lack of endoscopic visualization of intestinal villi with the â€œimmersion techniqueâ€•in overt atrophic celiac disease. Gastrointestinal Endoscopy, 2003, 57, 348-351. | 1.0 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Post-cholecystectomy alkaline reactive gastritis. European Journal of Gastroenterology and Hepatology, 2003, 15, 975-979. | 1.6 | 18 |
| 290 | Worsening of Gastroesophageal Reflux Symptoms in Professional Singers During Performances. Journal of Clinical Gastroenterology, 2003, 36, 403-404. | 2.2 | 12 |
| 291 | Gastric Surgery as a Long-term Risk Factor for Malignant Lesions of the Larynx. Archives of Surgery, 2003, 138, 751. | 2.2 | 13 |
| 292 | Bile reflux as possible risk factor in laryngopharyngeal inflammatory and neoplastic lesions. Acta Otorhinolaryngologica Italica, 2003, 23, 377-82. | 1.5 | 25 |
| 293 | Levofloxacin based regimens for the eradication of Helicobacter pylori. European Journal of Gastroenterology and Hepatology, 2002, 14, 1309-1312. | 1.6 | 62 |
| 294 | Relationship Between Gastric Localization of Hepatitis C Virus and Mucosa-associated Lymphoid Tissue in Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology, 2002, 37, 1126-1132. | 1.5 | 6 |
| 295 | Mono, dual and triple moxifloxacinâ€based therapies for Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2002, 16, 527-532. | 3.7 | 47 |
| 296 | The Role of Acid and Alkaline Reflux in Laryngeal Squamous Cell Carcinoma. Laryngoscope, 2002, 112, 1861-1865. | 2.0 | 91 |
| 297 | Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. American Journal of Gastroenterology, 2002, 97, 2744-2749. | 0.4 | 299 |
| 298 | EUS in the diagnosis of collagenous colitis. Gastrointestinal Endoscopy, 2001, 54, 113-115. | 1.0 | 6 |
| 299 | Relationship between gastric localization of HCV and gastric, H. pylori-related lymphoid tissue. Journal of Hepatology, 2001, 34, 130. | 3.7 | 0 |
| 300 | Relationship between gastric localization of hepatitis C virus and gastric mucosa-associated lymphoid tissue related to Helicobacter pylori infection. Gastroenterology, 2001, 120, A746-A747. | 1.3 | 0 |
| 301 | Link Between Helicobacter pylori Infection and Iron-Deficiency Anaemia in Patients with Coeliac Disease. Scandinavian Journal of Gastroenterology, 2001, 36, 1284-1288. | 1.5 | 26 |
| 302 | Prevalence of and risk factors for Helicobacter pylori infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study. European Journal of Gastroenterology and Hepatology, 2001, 13, 185-189. | 1.6 | 13 |
| 303 | The effect of oral administration of Lactobacillus GG on antibioticâ€associated gastrointestinal sideâ€effects during Helicobacter pylori eradication therapy. Alimentary Pharmacology and Therapeutics, 2001, 15, 163-169. | 3.7 | 245 |
| 304 | Effect of <i>Lactobacillus GG</i> Supplementation on Antibiotic-Associated Gastrointestinal Side Effects during <i>Helicobacter pylori</i> Eradication Therapy: A Pilot Study. Digestion, 2001, 63, 1-7. | 2.3 | 155 |
| 305 | Benign and malignant laryngeal lesions in patients with different type of surgical resection of the stomach. Gastroenterology, 2001, 120, A423-A423. | 1.3 | 0 |
| 306 | Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with H. pylori infection. Could the two neoplasms share a common pathogenesis?. Hepato-Gastroenterology, 2001, 48, 104-6. | 0.5 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Helicobacter pylori Eradication and Remission of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. Journal of Clinical Gastroenterology, 2000, 31, 169-171. | 2.2 | 36 |
| 308 | Is there an antigenic mimicry between arteriosclerotic lesions and H. pylori antigens?. Clinical Biochemistry, 2000, 33, 419-421. | 1.9 | 6 |
| 309 | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2000, 14, 73-77. | 3.7 | 16 |
| 310 | Efficacy of two oneâ€week rabeprazole/levofloxacinâ€based triple therapies for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2000, 14, 1339-1343. | 3.7 | 146 |
| 311 | A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Alimentary Pharmacology and Therapeutics, 2000, 14, 1625-1629. | 3.7 | 204 |
| 312 | Celiac disease and autoimmune endocrine disorders. Digestive Diseases and Sciences, 2000, 45, 1470-1471. | 2.3 | 1 |
| 313 | Is the alkaline reflux a risk factor for laryngeal lesions?. American Journal of Gastroenterology, 2000, 95, 2398-2398. | 0.4 | 12 |
| 314 | Gastric Mucosal Lesions in Celiac Patients. American Journal of Gastroenterology, 2000, 95, 1364-1365. | 0.4 | 1 |
| 315 | Is there any relationship between IEL and lymphoid follicles in the gastric mucosa? Reply. Gut, 2000, 47, 314-315. | 12.1 | 0 |
| 316 | Helicobacter pylori infection and autoimmune pathogenesis of gastric neoplasias. Gut, 2000, 46, 293d-293. | 12.1 | 4 |
| 317 | Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet, The, 2000, 356, 1494-1495. | 13.7 | 118 |
| 318 | Factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Gastroenterology, 2000, 118, A1363. | 1.3 | 0 |
| 319 | Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case against. Digestive and Liver Disease, 2000, 32, 65-68. | 0.9 | 17 |
| 320 | Long-term omeprazole treatment and risk of gastric cancer. Gastroenterology, 2000, 119, 1176-1177. | 1.3 | 2 |
| 321 | Role of sucralfate in gastrointestinal diseases. Panminerva Medica, 2000, 42, 55-9. | 0.8 | 11 |
| 322 | Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection. Hepato-Gastroenterology, 2000, 47, 1176-9. | 0.5 | 0 |
| 323 | Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. Digestive Diseases and Sciences, 1999, 44, 2386-2389. | 2.3 | 6 |
| 324 | Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology, 1999, 11, 247-250. | 1.6 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology, 1999, 11, 713-716. | 1.6 | 33 |
| 326 | Eradication of Helicobacter pylori in routine clinical practice: doubts and uncertainties. Hepato-Gastroenterology, 1999, 46, 312-5. | 0.5 | 1 |
| 327 | Minimal endoscopic aspects of gastric low-grade malt-lymphoma. Hepato-Gastroenterology, 1999, 46, 2818-22. | 0.5 | 1 |
| 328 | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. Alimentary Pharmacology and Therapeutics, 1998, 12, 539-543. | 3.7 | 13 |
| 329 | Helicobacter pylori infection and idiopathic arrhythmias. Gastroenterology, 1998, 114, A123. | 1.3 | 0 |
| 330 | Regression of autoimmune thrombocytopenic purpura after Helicobacter pylori eradication. Gastroenterology, 1998, 114, A124. | 1.3 | 4 |
| 331 | Role of Helicobacter pylori infection in dyspepsia. Gastroenterology, 1998, 114, A130. | 1.3 | 0 |
| 332 | Variation of the endoscopic pattern of low-grade gastric malt-lymphoma after Helicobacter pylori eradication. Gastrointestinal Endoscopy, 1998, 48, 231-232. | 1.0 | 5 |
| 333 | Disappearance of Gastric Mucosa-Associated Lymphoid Tissue in Coeliac Patients after Gluten Withdrawal. Scandinavian Journal of Gastroenterology, 1998, 33, 401-405. | 1.5 | 25 |
| 334 | Association of Virulent Helicobacter pylori Strains With Ischemic Heart Disease. Circulation, 1998, 97, 1675-1679. | 1.6 | 299 |
| 335 | Oxatomide in Food Allergies. Comparative Study versus Disodium Chromoglycate. International Journal of Immunopathology and Pharmacology, 1998, 11, 149-154. | 2.1 | 3 |
| 336 | Helicobacter pylori infection and ischaemic heart disease. Italian Journal of Gastroenterology and Hepatology, 1998, 30 Suppl 3, S304-6. | 0.5 | 3 |
| 337 | What is the best azithromycin-based therapy for Helicobacter pylori infection?. Journal of Antimicrobial Chemotherapy, 1997, 39, 111-111. | 3.0 | 1 |
| 338 | Endoscopic findings and clinical patterns are not useful for distinguishing low from high grade gastric MALT lymphoma Â Reply. Gut, 1997, 41, 577-577. | 12.1 | 3 |
| 339 | Gastric Mucosa-Associated Lymphoid Tissue in Autoimmune Thyroid Diseases. Scandinavian Journal of Gastroenterology, 1997, 32, 869-872. | 1.5 | 27 |
| 340 | The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained byHelicobacter pylori. Scandinavian Journal of Gastroenterology, 1997, 32, 285-287. | 1.5 | 27 |
| 341 | 1.P.303 A new human atrial natruretic peptide gene C/T polymorphism is more frequent in type 1 microalbuminuric diabetic patients. Atherosclerosis, 1997, 134, 81. | 0.8 | 0 |
| 342 | Pathogenesis of MALT lymphoma: An antigen-dependent process. Gastroenterology, 1997, 113, 1810. | 1.3 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | CD4-Mediated Anchoring of the Seminal Antigen gp17 onto the Spermatozoon Surface. Human Immunology, 1997, 58, 30-41. | 2.4 | 30 |
| 344 | Editorial: The Role of Endoscopy in the Diagnosis and Follow-up of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Journal of Clinical Gastroenterology, 1997, 25, 496-498. | 2.2 | 5 |
| 345 | Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. Italian Journal of Gastroenterology and Hepatology, 1997, 29, 361-4. | 0.5 | 3 |
| 346 | Coeliac disease and follicular gastritis. Lancet, The, 1996, 347, 268. | 13.7 | 20 |
| 347 | Eradication of Helicobacter pylori as the first step in the treatment of peptic stenosis. Gastrointestinal Endoscopy, 1996, 44, 757. | 1.0 | 1 |
| 348 | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. Alimentary Pharmacology and Therapeutics, 1996, 10, 997-1000. | 3.7 | 32 |
| 349 | Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.. Alimentary Pharmacology and Therapeutics, 1996, 10, 285-288. | 3.7 | 27 |
| 350 | Association of Helicobacter pylori infection, lymphoid follicles, and lymphocytic gastritis: a risk factor for the development of primary gastric lymphoma?. Gut, 1996, 38, 792-792. | 12.1 | 4 |
| 351 | Role of Dental Plaque in the Transmission of Helicobacter Pylori Infection. Journal of Clinical Gastroenterology, 1996, 22, 174-177. | 2.2 | 65 |
| 352 | Helicobacter Pylori Eradication Helps Resolve Pyloric and Duodenal Stenosis. Journal of Clinical Gastroenterology, 1996, 23, 157-158. | 2.2 | 26 |
| 353 | Prevention and Treatment of Low-grade B-cell Primary Gastric Lymphoma by Anti-H. Pylori Therapy. Journal of Clinical Gastroenterology, 1995, 21, 118-122. | 2.2 | 53 |
| 354 | A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. European Journal of Immunology, 1995, 25, 1461-1464. | 2.9 | 58 |
| 355 | Omeprazole versus ranitidine in the prevention of duodenal ulcer recurrence after eradication therapy. Current Therapeutic Research, 1995, 56, 568-572. | 1.2 | 1 |
| 356 | Effect of anti-Helicobacter pylori therapy on inflammatory cell infiltration and acquired malt in gastric mucosa: A morphometric study by means of computer-assisted image analysis. Gastroenterology, 1995, 108, A48. | 1.3 | 0 |
| 357 | Disappearance of gastric acquired malt and regression of low-grade B-cell gastric lymphoma by means anti-H. pylori treatment. Gastroenterology, 1995, 108, A65. | 1.3 | 0 |
| 358 | Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric lymphoma. Lancet, The, 1995, 345, 192. | 13.7 | 47 |
| 359 | Partial nucleotide sequencing of six subtype 2c hepatitis C viruses detected in Italy. Journal of Clinical Microbiology, 1995, 33, 2781-2784. | 3.9 | 30 |
| 360 | A fungal metabolite which inhibits the interaction of CD4 with major histocompatibility complex-encoded class II molecules. European Journal of Immunology, 1994, 24, 991-998. | 2.9 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Helicobacter pylori and the Anatomoclinical Spectrum of Duodenal Ulcer Disease. Journal of Clinical Gastroenterology, 1994, 18, 239. | 2.2 | 0 |
| 362 | Identification of a CD4 binding site on the Î²2 domain of HLA-DR molecules. Nature, 1992, 356, 799-801. | 27.8 | 277 |